

**Проф. Д-р Румяна Донкова Марковска**



**Професор към Катедрата по медицинска микробиология**

**E - mail:** [rmarkovska@medfac.mu-sofia.bg](mailto:rmarkovska@medfac.mu-sofia.bg)

**Професионален опит**

От 06.2020 г - професор към Катедрата по медицинска микробиология, МУ-София

2012г – 06.2020 г - доцент към Катедрата по медицинска микробиология, МУ-София

1997 г – 07.2012г асистент/старши/главен асистент към Катедра по медицинска микробиология, МУ-София

**Образование**

Висше – Медицина – 1994, МУ- София

Специалност микробиология - взета 2000 г.

2007 г защитена дисертация – образователна и научна степен “доктор”

**Научни интереси**

Антимикробна химиотерапия

Антимикробна резистентност: Механизми, епидемиология, генетика и тестове за определяне на чувствителността

Фактори на вирулентност

Order Enterobacterales, *Helicobacter pylori*, *Clostridiooides difficile*

### **Членство в професионални организации**

Българското дружество по медицинска микробиология; Европейското дружество по клинична микробиология и инфекциозни болести (ESCMID); Българска асоциация на микробиолозите

### **Отличия**

2012г – Награда “Акад д-р Д.Ораховец” за високи постижения в областта на медицинската наука и преподаване

Грант за участие в 9th ESCMID курс - Verona, Италия - 1999 и 16th ESCMID курс Антalia, Турция - 2001;

ESCMID Грант “Training in Foreign Laboratories” - 2004 г - Мюнхен, Германия

Два гранта “free registration”, за участие в 14 ECCMID, Прага, Чехия и 16 ECCMID, Ница, Франция

### **Специализации**

Мюнхен, Германия Май 2001 –изоелектрично фокусиране,

Мюнхен, Германия Юни, 2004, Мюнхен, Германия Юли, 2010– полимеразо-верижна реакция, нуклеотидно секвениране, молекуларно-генетични техники за епидемиологично проучване.

### **Научна активност**

112 научни публикации, вкл. 64 в списания с импакт фактор

Цитирания – над 500 h индекс - 16

Докторанти – 6, от които защитили 5 и един в начален етап.

Дипломанти - 2

Проекти към Съвета по медицинска наука като водещ изследовател – 14

Проекти към Съвета по медицинска наука като участник - 19

Проекти към Съвета по медицинска наука като участник Към Фонда за научни изследвания – МОН – 3.

ORCID <https://orcid.org/0000-0003-1634-8768>

Research gate <https://www.researchgate.net/profile/Rumyana-Markovska>

### Списък на представителни публикации с импакт фактор

- 1 C. **Markovska R**, Schneider I, Keuleyan E, and Bauernfeind A. 2004 Extended spectrum beta-lactamase( ESBL) CTX-M-15 producing *E. coli* and *K. pneumoniae* in Sofia, Bulgaria , Clinical Microbiology Infection 8, 752- 755 **IF<sub>2004</sub>-2,36**
- 2 C. Bijev A, Nankov A, Keuleyan E, **Markovska R**, and Daneva E. 2004. Synthesis and Preliminary antimicrobial evaluation of new 7-(N-pyrrolyl) derivatives of cephalosporins. Azneim.-Forsch/Drug Res 54, 2, 119-124 **IF<sub>2004</sub>-0,65**
- 3 C. **Markovska R**, Rachkova K, Schneider I, Keuleyan E and Bauernfeind A. (2005) “Multiresistant SHV-2 Producing *Salmonella Enterica* Serotype *Corvallis* In Bulgaria” Journal of Chemotherapy 17, 568-569 **IF<sub>2005</sub>-1,47**
- 4 C. **Markovska R**, Keuleyan E, Schneider I, Markova B, Rachkova K, Sredkova M, and Bauernfeind A. 2006. CTX-M-3 Extended Spectrum Beta-Lactamase producing *K. pneumoniae* and dissemination of the plasmidic blaCTX-M-3 in Bulgaria. Eur. J. Clin. Microbiol. Infect. Dis. 25; 123-125 **IF<sub>2006</sub>-2,33**
- 5 C. Schneider I, **Markovska R**, Keuleyan E, Sredkova M, Rachkova K, Mitov I, Bauernfeind A. Dissemination and persistence of a plasmid-mediated TEM-3-like beta-lactamase, TEM-139, among *Enterobacteriaceae* in Bulgaria. Int J Antimicrob Agents. 2007; 29(6): 710-714. **IF<sub>2007</sub>-2,338**
- 6 C. Schneider I, Keuleyan E, Rasshofer R, **Markovska R**, Queenan AM, Bauernfeind A. 2008. VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in *Pseudomonas aeruginosa* isolates from Bulgaria and Germany. Antimicrob Agents Chemother. 52(8):2977-2979.**IF<sub>2008</sub> - 4.716**
- 7 C. Ivanova D, **Markovska R**, Hadjieva N, Schneider I, Mitov I, Bauernfeind A. 2008. Extended-spectrum beta-lactamase-producing *Serratia marcescens* outbreak in a Bulgarian hospital. J Hosp Infect. 70(1):60-65. **IF<sub>2008</sub>-2.956**
- 8 C. **Markovska R**, Schneider I., Keuleyan E., Sredkova M., Ivanova D., Markova B., Lazarova G, Dragijeva E., Savov E, Haydouchka I, Hadjieva N, Setchanova L, Mitov I., Bauernfeind A.. 2008. Extended-spectrum beta-lactamase-producing *Enterobacteriaceae* in Bulgarian hospitals. Microb Drug Resist. 14(2):119-128. **IF<sub>2008</sub> - 1.8**
- 9 C. Stoeva T, Higgins PG, Savov E, **Markovska R**, Mitov I, Seifert H. 2009. Nosocomial spread of OXA-23 and OXA-58 beta-lactamase producing *Acinetobacter baumanii* in Bulgarian hospitals. J Antimicrob Chemother. 63(3):618-620. **IF<sub>2009</sub> - 4.352**

- 10 C. Boyanova L., **Markovska R.**, Yordanov D., Marina M., Ivanova K., Panayotov S., Gergova G., Mitov I. 2009. High prevalence of virulent *Helicobacter pylori* strains in symptomatic Bulgarian patients. *Diagn Microbiol Infect Dis.* 64 (4): 374-380. **IF 2009 – 2.451**
- 11 C. **Markovska R**, Boyanova L, Yordanov D, Gergova G, Mitov I. *Helicobacter pylori oipA* genetic diversity and its associations with both disease and *cagA*, *vacA* s, m and i alleles among Bulgarian patients. *Diagn Microbiol Infect Dis.*; 2011;71(4):335-40 **IF<sub>2011-2,528</sub>**
- 12 C. Strateva T, Markova B, **Markovska R**, Marteva-Proevska Y, Ivanova D, Mitov I. Emergence of 16s rRNA methylase-producing nosocomial *Acinetobacter baumannii* isolates in a university hospital in Bulgaria. 2011; *J Chemother.* 23(6):374-5 **IF<sub>2011-0.825</sub>**
- 13 C. **Markovska R**, I Schneider, D Ivanova, E Keuleyan, T Stoeva, M Sredkova, B Markova, K Bojkova, R Gergova, A Bauernfeind, I Mitov. High prevalence of CTX-M-15-producing O25b-ST131 *Escherichia coli* clone in Bulgarian hospitals. *Microb Drug Resist;* 2012;18(4):390-5 **IF<sub>2012-2,364</sub>**
- 14 C. **R. Markovska**, I. Schneider, Y. Marteva-Proevska, I. Mitov, A. Bauernfeind, B. Markova . First detection of the AmpC beta-lactamase ACC-1 in a *Klebsiella pneumoniae* isolate in Bulgaria *J Chemotherapy* 2012; 24(5):307-308 **IF<sub>2012-0.83</sub>**
- 15 C. **Markovska R**, Schneider I, Stoeva T, Bojkova K, Boyanova L, Bauernfeind A, Mitov I. First identification of KPC-2 and VIM-1 producing *Klebsiella pneumoniae* in Bulgaria. *Diagn Microbiol Infect Dis.* 2013;Nov;77(3):252-3. C **IF<sub>2013-2,568</sub>**
- 16 C. Schneider I, **Markovska R**, Marteva-Proevska Y, Mitov I, Markova B, Bauernfeind A. Detection of CMY-99, a Novel Acquired AmpC-Type β-Lactamase, and VIM-1 in *Proteus mirabilis* Isolates in Bulgaria. *Antimicrob Agents Chemother.* 2014; Jan;58(1):620-1. **IF<sub>2014- 4.48</sub>**
- 17 C. **Markovska RD**, Stoeva TJ, Bojkova KD, Mitov IG. Epidemiology and Molecular Characterization of Extended-Spectrum Beta-Lactamase-Producing Enterobacter spp., *Pantoea agglomerans*, and *Serratia marcescens* Isolates from a Bulgarian Hospital. *Microb Drug Resist. Microb Drug Resist.* 2014 Apr;20(2):131-7. **IF<sub>2014-2,49</sub>**
- 18 C. **Markovska R**, Schneider I, Ivanova D, Mitov I, Bauernfeind A. Predominance of IncL/M and IncF plasmid types among CTX-M-ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* in Bulgarian hospitals. *APMIS.* 2014; Jul;122(7):608-15. **IF<sub>2014-2,042</sub>**
- 19 C. **Markovska R**, Stoeva T, Schneider I, Boyanova L, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. *APMIS.* 2015 Oct;123(10):887-94 **IF<sub>2015-1,93</sub>**
- 20 C. Boyanova L, **Markovska R**, Mitov I. Review article: virulence arsenal of the most pathogenic species among the Gram positive anaerobic cocci, *Finegoldia magna*. *Anaerobe.* 2016; **42:145-151.** **IF<sub>2016: 2,278</sub>**
- 21 C. **Markovska R**, Schneider I, Keuleyan E, Ivanova D, Lesseva M, Stoeva T, Sredkova M, Bauernfeind A, Mitov I. Dissemination of a Multidrug-Resistant VIM-1- and CMY-99-Producing *Proteus mirabilis* Clone in Bulgaria. *Microb Drug Resist.* 2017; Apr;23(3):345-350 **IF<sub>2017-2,34</sub>**

- 22 C. **Markovska R**, Stoeva T, Boyanova L, Stankova P, Pencheva D, Kaneva R, Mitev V, Mitov I. Isolation of *Escherichia coli* ST131 producing KPC-2 in Bulgaria. *Infect Dis (Lond)*. 2017; May;49(5):429-431 **IF<sub>2017</sub>: 1.932**
- 23 C. **Markovska R**, Stoeva T, Boyanova L, Stankova P, Pencheva D, Keuleyan E, Murjeva M, Sredkova M, Ivanova D, Lazarova G, Nedelcheva G, Kaneva R, Mitov I. Dissemination of successful international clone ST15 and clonal complex 17 among Bulgarian CTX-M-15 producing *K. pneumoniae* isolates. *Diagn Microbiol Infect Dis*. 2017; Dec;89(4):310-313. doi: 10.1016/j.diagmicrobio.2017.08.012. **IF<sub>2017</sub>: 2.34**
- 24 C. **Markovska R**, Keuleyan E, Stankova P, Boyanova L, Stoeva T, Murjeva M, Sredkova M, Ivanova D, Lazarova G, Nedelcheva G, I Mitov. Antimicrobial susceptibility of clinically significant isolates of *Klebsiella pneumoniae* and *Escherichia coli* resistant to cephalosporins third generation collected from patients in Bulgarian hospitals. *C. R. Acad. Bulg. Sci.* 2018; 71(8):1130-38 **IF<sub>2018</sub> - 0,321**
- 25 C. **Markovska R**, Boyanova L, Yordanov D, Stankova P, Gergova G, Mitov I. Status of *Helicobacter pylori* cag pathogenicity island (cagPAI) integrity and significance of its individual genes. *Infect Genet Evol*. 2018;59:167-171. **IF<sub>2018</sub>: 2.61**
- 26 C. **Markovska R**, Stoeva T, Boyanova L, Stankova P, Schneider I, Keuleyan E, Mihova K, Murdjeva M, Sredkova M, Lesseva M, Nedelcheva G, Petrova A, Ivanova D, Lazarova G, Kaneva R, Mitov I. Multicentre investigation of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing *K. pneumoniae*. *Infect Genet Evol*. 2019; Apr;69:61-67. **IF<sub>2018</sub>-2,611**
- 27 C. Boyanova L, **Markovska R**, Hadzhiyski P, Yordanov D, Yaneva P, Mitov I. Recurrent *Clostridioides* (*Clostridium*) difficile infection in a patient suffering from inflammatory bowel disease and benefits of resistotyping. *Diagn Microbiol Infect Dis*. 2019; 94(4):334-336 **IF<sub>2018</sub>-2,314**
- 28 C. **Markovska R**, Stoeva T, Stankova P, Boyanova L, Dimitrova D, Gergova R, Mitov I. First report of *Enterobacter asburiae* isolate, producing NDM-1 and a novel ACT-68 enzyme in Bulgaria. *Infect Dis (Lond)*. 2019 Aug;51(8):627-629. **IF<sub>2018</sub>-2,494**
- 29 C. **Markovska R**, Stoeva T, Dimitrova D, **Boyanova L**, Stankova P, Mihova K, Mitov I. Quinolone resistance mechanisms among third generation cephalosporin resistant isolates of *Enterobacter* spp. in a Bulgarian university hospital. *Infect Drug Resist*. 2019;12: 1445–1455. **(IF<sub>2017</sub> 3,779)**
- 30 C. Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in *Helicobacter pylori*: current state and future directions. *Expert Rev Clin Pharmacol*. 2019; Aug 28:1-7. doi: 10.1080/17512433.2019.1654858. **(IF<sub>2018</sub> 2.776)**
- 31 C. Boyanova L, Kalvatchev N, Yordanov D, Hadzhiyski P, **Markovska R**, Gergova G, Mitov I. *Clostridioides* (*Clostridium*) difficile carriage in asymptomatic children since 2010: a narrative review. *Biotechnol Biotec Eq*. 2019; 33:1, 1228-1236, DOI: 10.1080/13102818.2019.1650666 **(IF<sub>2018</sub> 1.227)**
- 32 C. Boyanova L, **Markovska R**, Mitov I. Multidrug resistance in anaerobes. *FutureMicrobiol*. 2019; **14**(12):1055–1064. **(IF<sub>2018</sub> 2.746)**
- 33 C. **Markovska R**, Stankova P, Stoeva T, Ivanova D, Pencheva D, Kaneva R, Boyanova L. Fecal Carriage and Epidemiology of Extended-Spectrum Beta-Lactamase/Carbapenemases Producing Enterobacteriales Isolates in Bulgarian Hospitals. *Antibiotics (Basel)*. 2021 Jun 20;10(6):747